European Society for Medical Oncology Congress | Conference

Scott Tagawa, MD, on Data Regarding Treatment Patterns and Survival for Metastatic Castration-Sensitive Prostate Cancer
October 29, 2021

Scott Tagawa, MD, spoke about the implications of the results from his research on treatment patterns of patients with metastatic castration-sensitive prostate cancer, as well as the need for further studies with other data sets.

Brian Rini, MD, on Expectations For a Trial Examining MK-1308A Plus Lenvatinib and Pembrolizumab With Other Combinations in ccRCC
October 22, 2021

Brian I. Rini, MD, detailed the focus, goals, and key end points of a 3-arm, phase 3 trial comparing MK-1308A or belzutifan plus lenvatinib and pembrolizumab to the control of lenvatinib and pembrolizumab alone to treat patients with advanced clear cell renal cell carcinoma.

Alicia Morgans, MD, MPH, Discusses Outcomes From the CARD Trial in mCRPC at 2021 ESMO
October 16, 2021

CancerNetwork® sat down with Alicia Morgans MD, MPH, at the 2021 European Society for Medical Oncology to talk survival and progression outcomes from the CARD trial in patients with metastatic castration-resistant prostate cancer.

Alicia Morgans, MD, MPH, Discusses How a Hypothetical Trial Cohort Demonstrates Impacts of Cabazitaxel Costs/Complications in mCRPC
October 13, 2021

CancerNetwork® sat down with Alicia Morgans MD, MPH, at the 2021 European Society for Medical Oncology to discuss how a hypothetical cohort from the CARD trial highlighted the impact of treatment with cabazitaxel on costs and complications in patients with metastatic castration-resistant prostate cancer.

Andrew Armstrong, MD, MSc, Discusses Key Findings From ARCHES in mHSPC at 2021 ESMO
October 10, 2021

CancerNetwork® sat down with Andrew Armstrong, MD, MSc, at the 2021 European Society for Medical Oncology Congress to talk about overall survival results found the phase 3 ARCHES study.

Enzalutamide Plus Androgen Deprivation Therapy Demonstrates Durable Overall Survival Benefit in mHSPC
October 06, 2021

Men with metastatic hormone-sensitive prostate cancer who were treated with enzalutamide plus androgen deprivation therapy experienced an improved, long-lasting overall survival compared with those who received placebo.

Alicia Morgans, MD, MPH, Discusses Differences in Complications and Costs With Cabazitaxel vs a Second Androgen Receptor Targeted Agent in mCRPC
September 28, 2021

CancerNetwork® sat down with Alicia Morgans MD, MPH, at the 2021 European Society for Medical Oncology to talk about key findings observed when utilizing cabazitaxel vs a second androgen receptor targeted agent in metastatic castration-resistant prostate cancer.

Notable PFS Benefit, Significant Intracranial Response Observed With Brigatinib Vs Crizotinib in ALK+ NSCLC
September 27, 2021

Final read-out of progression-free survival data from the ALTA-1L trial indicates significant benefit of brigatinib versus crizotinib for patients with ALK-positive non–small cell lung cancer who have not previously received an ALK inhibitor.

Safety Profile Remains Consistent When Darolutamide Is Added to ADT for nmCRPC
September 26, 2021

Acceptable safety was noted with the addition of darolutamide to androgen deprivation therapy and resulted in infrequent extra adverse effects versus placebo in men with nonmetastatic castration-resistant prostate cancer.

Ravi Madan, MD, Discusses Key Findings Utilizing PET Imaging and Tc99 Scans in Conjunction With Enzalutamide in mCRPC
September 24, 2021

Ravi Madan, MD, discusses clinical findings utilizing PET imaging and Tc99 scans in patients with metastatic castration-resistant prostate cancer who are being treated with enzalutamide